Company to Present and Participate in Panel Discussions at DIA Conference in Bethesda, Maryland April 29-May 1, 2009
SANTA CLARA, Calif., April 7 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that senior leadership will present clinical data, discuss applications for its proprietary technology, and participate in panel discussion at the Drug Information Association (DIA) Cardiovascular Safety and QT/Arrhythmia Assessment in Drug Development - Optimizing Drug Development Conference. The conference, co-sponsored by the FDA and the Heart Rhythm Society, is scheduled from April 29 through May 1, 2009 in Bethesda, Maryland.
Dr. Ihor Gussak, NewCardio's Vice President and Chief Medical Officer, will discuss Automatic ECG Analysis, based on the Company's proprietary three-dimensional platform and its QTinno(TM) solution. This is a special session on Automatic QT Assessment and multiple investigators are being asked to provide a structured discussion, covering technical approaches, including how analysis is performed, for emerging technologies, validation data, the amount of over-reading necessary, morphology analysis and an evaluation of risk factors. Dr. Gussak will participate in conference panel discussions as well.
In addition, the Company has been invited to make a second presentation, "Differential Effects of D-Sotalol and a Flouroquinolone Antibiotic on T-wave Morphology and Ventricular Repolarization." Dr. Gussak will also make this presentation and participate in a subsequent discussion.
The DIA conference will feature regulatory, industry, and scientific leaders from around the world who will discuss the evolution of drug development, cardiac repolarization, and cardiovascular (CV) safety. This open forum will discuss the new direction in the development of pharmaceutical agents, practical challenges and possible solutions, ways of challenging the current science, and regulatory approaches. More information on this conference is available at http://www.diahome.org/ online.
Branislav Vajdic, PhD, NewCardio's Chief Executive Officer, commented, "This conference is an ideal venue for NewCardio to discuss the technical aspects and the exceptional accuracy of our QTinno solution for fully automated ECG analysis in clinical drug trials. This well-attended and high-profile conference is focused on optimizing drug development, specifically as it relates to QT and arrhythmia assessment, and the QTinno solution is an ideal technology to advance this important goal. We look forward to sharing the results of our validation studies, demonstrating the proven accuracy of QTinno and answering questions from investigators and industry leaders."
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit www.newcardio.com.
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2008 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
Investor Contact: Hayden IR Jeff Stanlis Partner and Vice President of Communications (602) 476-1821 email@example.com
|SOURCE NewCardio, Inc.|
Copyright©2009 PR Newswire.
All rights reserved